Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242619 · ClinicalTrials.gov registry record · NA
Insulin Resistance in Patients With Mood Disorder
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00242619: Completed NA study, sponsored by Stanford University.
NCT00242619 is a NA study that has completed, run by Stanford University. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00242619, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
Insulin resistance is known to be associated with mood disorders and cognitive difficulties. The purpose of this study is to treat depressed patients with rosiglitazone (also known as \[AKA\] Avandia), therefore improving glucose sensitivity, which in turn has the potential to affect mood and thinking. We, the researchers at Stanford University, are recruiting men and women who have been diagnosed with depression, and are willing to participate in this 3 month study. Participation involves neuropsychological testing, 2 blood draws called an oral glucose tolerance test (OGTT), which tests for glucose and insulin levels, and the medication, rosiglitazone. Participants are allowed to continue on their current psychiatric medication.
Interventions
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00242619
The ClinicalTrials.gov registry entry for NCT00242619 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rosiglitazone is the first listed.
NCT00242619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00242619 about?
NCT00242619 is a clinical study titled "Insulin Resistance in Patients With Mood Disorder". Insulin resistance is known to be associated with mood disorders and cognitive difficulties. The purpose of this study is to treat depressed patients with rosiglitazone (also known as \[AKA\] Avandia), therefore improving glucose sensitivity, which in turn has the potential to affect mood and thinki...
What is the current status of trial NCT00242619?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2007-07. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00242619?
The interventions under investigation include: rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00242619?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.